Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A1 | P30531 | 4/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3842807 | 0.95 | SLC6A1 (0.50) | SLC6A1ALDH1A1LMNACYP1A2CYP2D6 | |
| SCHEMBL3841017 | 0.92 | — | — | |
| SCHEMBL3837949 | 0.89 | BCHE (0.51) | CYP1A2CYP2D6CYP2C9TSHRNFKB1 | |
| SCHEMBL883999 | 0.89 | SMN1; SMN2 (0.44) | SLC6A1ALDH1A1LMNACYP1A2CYP2D6 | |
| SCHEMBL3865049 | 0.87 | SLC6A1 (0.55) | SLC6A1ALDH1A1LMNACYP1A2CYP2D6 | |
| SCHEMBL28959996 | 0.87 | BCHE (0.55) | CYP1A2CYP2D6CYP2C9TSHRNFKB1 | |
| SCHEMBL3841038 | 0.85 | SLC6A1 (0.54) | SLC6A1ALDH1A1LMNACYP1A2CYP2D6 | |
| SCHEMBL3839566 | 0.85 | SLC6A1 (0.54) | SLC6A1ALDH1A1LMNACYP1A2CYP2D6 | |
| SCHEMBL3838182 | 0.84 | SLC6A1 (0.52) | SLC6A1ALDH1A1LMNACYP1A2CYP2D6 | |
| SCHEMBL6360035 | 0.84 | SLC6A1 (0.52) | SLC6A1ALDH1A1LMNACYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11306078-B2 | Piperidine CXCR7 receptor modulators | IDORSIA PHARMACEUTICALS LTD. (CH) | 2022-04-19 | — | — | US | disclosed |
| EP-1931341-B1 | 1H-INDOLE-PYRIDINECARBOXAMIDE AND 1H-INDOLE-PIPERIDINECARBOXAMIDE DERIVATIVES AND THEIR USE AS TYROSINE HYDROXYLASE INDUCERS | SERVIER LAB (FR) | 2009-11-04 | — | — | EP | disclosed |
| US-20080274107-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. | 2008-11-06 | — | — | US | disclosed |
| US-20080274107-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. | 2008-11-06 | — | — | US | disclosed |
| US-20070149538-A1 | Diarylamine-Containing Compounds and Compositions, and their use as Modulators of C-Kit Receptors | IRM LLC (BM) | 2007-06-28 | — | — | US | disclosed |
| US-7186723-B2 | Tyrosine kinase inhibitors | MERCK & CO., INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-7186723-B2 | Tyrosine kinase inhibitors | MERCK & CO., INC. (US) | 2007-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11306078-B2 | Piperidine CXCR7 receptor modulators | CXCR1, CXCR5, ACKR3 | SLC6A1 2342/4885ALDH1A1 434/4885LMNA 4843/4885 |
| US-20070149538-A1 | Diarylamine-Containing Compounds and Compositions, and their use as Modulators of C-Kit Receptors | KIT, PRKCH, PRKCE | SLC6A1 3509/4885ALDH1A1 1472/4885LMNA 710/4885 |
| US-20080274107-A1 | Tyrosine kinase inhibitors | ERBB2, TYRO3, TIE1 | SLC6A1 4731/4885ALDH1A1 3104/4885LMNA 3751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.